Cancers (Aug 2022)

Multidisciplinary Tumor Board in the Management of Patients with Colorectal Liver Metastases: A Single-Center Review of 847 Patients

  • Flavio Milana,
  • Simone Famularo,
  • Antonio Luberto,
  • Lorenza Rimassa,
  • Marta Scorsetti,
  • Tiziana Comito,
  • Tiziana Pressiani,
  • Ciro Franzese,
  • Dario Poretti,
  • Luca Di Tommaso,
  • Nicola Personeni,
  • Marcello Rodari,
  • Vittorio Pedicini,
  • Matteo Donadon,
  • Guido Torzilli

DOI
https://doi.org/10.3390/cancers14163952
Journal volume & issue
Vol. 14, no. 16
p. 3952

Abstract

Read online

There is still debate over how reviewing oncological histories and addressing appropriate therapies in multidisciplinary team (MDT) discussions may affect patients’ overall survival (OS). The aim of this study was to describe MDT outcomes for a single cancer center’s patients affected by colorectal liver metastases (CRLMs). From 2010 to 2020, a total of 847 patients with CRLMs were discussed at our weekly MDT meeting. Patients’ characteristics and MDT decisions were analyzed in two groups: patients receiving systemic therapy (ST) versus patients receiving locoregional treatment (LRT). Propensity-score matching (PSM) was run to reduce the risk of selection bias. The median time from MDT indication to treatment was 27 (IQR 13–51) days. The median OS was 30 (95%CI = 27–34) months. After PSM, OS for patients undergoing LRT was 51 (95%CI = 36–64) months compared with 15 (95%CI = 13–20) months for ST patients (p < 0.0001). In this large retrospective study, the MDT discussions were useful in providing the patients with all available locoregional options.

Keywords